A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01849874 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
341
Enrollment
INDUSTRY
Sponsor class

Stopped Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the planned interim efficacy analysis showed the hazard ratio for PFS crossed the predefined futility boundary.

Conditions

Interventions

Sponsor

Pfizer